Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine
May 17 2024 - 8:00AM
Oragenics, Inc. (NYSE American: OGEN), a pioneering pharmaceutical
company specializing in intranasal treatments for neurological
disorders, today announced that the company will host a webinar
panel on Neurotrauma Medicine Monday, May 20, 2024, at 12:00 PM ET.
The discussion will address the unmet medical need in Traumatic
Brain Injury (TBI), commonly known as concussion, explore common
causes, and examine its association with other long-term
neurological disorders. Additionally, the company will present its
lead drug candidate, ONP-002, an innovative neurosteroid designed
to treat mild TBI and discuss its outcomes from preclinical and
Phase I trials, as well as details of an upcoming Phase II clinical
trial to be conducted in acute and emergency departments. Details
for the webinar are as follows:
Webinar Topic: Neurotrauma
MedicineWhen: Monday, May 20,
2024Time: 12:00 PM Eastern Time
Register: Webinar
LinkSpeakers:
- James P. Kelly, MA, MD, FAAN, FANA, Emeritus Professor of
Neurology and PM&R, University of Colorado School of
Medicine
- Frank Peacock, IV, MD, FACEP, FACC, FESC, Vice Chair for
Emergency Medicine Research, Baylor College of Medicine
About Oragenics, Inc.Oragenics is a
development-stage biotechnology company focused on nasal delivery
of pharmaceutical medications in neurology and fighting infectious
diseases, including drug candidates for treating mild traumatic
brain injury (mTBI), also known as concussion, and for treating
Niemann Pick Disease Type C (NPC), as well as proprietary powder
formulation and an intranasal delivery device. For more
information, please visit www.oragenics.com.
Forward-Looking StatementsThis communication
contains “forward-looking statements” within the meaning of the
safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995, including without limitation statements
regarding the ability of the Company to timely and successfully
undertake Phase II clinical trials using its novel drug-device
combination for the treatment of mild Traumatic Brain Injury. These
forward-looking statements are based on management’s beliefs and
assumptions and information currently available. The words
"believe," "expect," "anticipate," "intend," "estimate," "project"
and similar expressions that do not relate solely to historical
matters identify forward-looking statements. Investors should be
cautious in relying on forward-looking statements because they are
subject to a variety of risks, uncertainties, and other factors
that could cause actual results to differ materially from those
expressed in any such forward-looking statements. These factors
include, but are not limited to: the Company’s ability to advance
the development of its product candidates, including the neurology
assets, under the timelines and in accord with the milestones it
projects; the Company’s ability to raise capital and obtain
funding, non-dilutive or otherwise, for the development of its
product candidates; the regulatory application process, research
and development stages, and future clinical data and analysis
relating to its product candidates, including any meetings,
decisions by regulatory authorities, such as the FDA and
investigational review boards, whether favorable or unfavorable;
the Company’s ability to obtain, maintain and enforce necessary
patent and other intellectual property protection; the nature of
competition and development relating to concussion treatments; the
Company’s expectations as to the outcome of preclinical studies and
clinical trials and the potential benefits, activity, effectiveness
and safety of its product candidates including as to
administration, transmission, manufacturing, storage and
distribution; and general economic and market conditions and risks,
as well as other uncertainties described in our filings with the
U.S. Securities and Exchange Commission. All information set forth
is as of the date hereof unless otherwise indicated. You should
consider these factors in evaluating the forward-looking statements
included and not place undue reliance on such statements. We do not
assume any obligation to publicly provide revisions or updates to
any forward-looking statements, whether as a result of new
information, future developments or otherwise, should circumstances
change, except as otherwise required by law.
Oragenics, Inc.Janet Huffman, Chief Financial
Officer813-286-7900jhuffman@oragenics.com
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024